Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough?

Elizabeth Miller ORCID logo; (2022) Predicting the efficacy of new coronavirus vaccines - Are neutralising antibodies enough? EBioMedicine, 79. 104034-. ISSN 2352-3964 DOI: 10.1016/j.ebiom.2022.104034
Copy

Identifying an immunological correlate of protection (CoP) is a key objective in vaccine development allowing licensure of new vaccines without direct evidence of efficacy. Having a CoP for COVID-19 vaccines is particularly important as establishing efficacy for new vaccine platforms in placebo-controlled trials is becoming ethically problematic with the growing availability of first generation vaccines with proven efficacy.


picture_as_pdf
Miller_etal_2022_Predicting-the-efficacy-of-new.pdf
subject
Published Version
Available under Creative Commons: NC-ND 4.0

View Download

Atom BibTeX OpenURL ContextObject in Span Multiline CSV OpenURL ContextObject Dublin Core Dublin Core MPEG-21 DIDL EndNote HTML Citation JSON MARC (ASCII) MARC (ISO 2709) METS MODS RDF+N3 RDF+N-Triples RDF+XML RIOXX2 XML Reference Manager Refer Simple Metadata ASCII Citation EP3 XML
Export

Downloads